Correction to: Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study
Adv Ther
.
2021 Aug;38(8):4599-4601.
doi: 10.1007/s12325-021-01813-8.
Authors
Ichiro Nakamura
1
,
Hiroshi Maegawa
2
,
Kazuyuki Tobe
3
,
Satoshi Uno
4
Affiliations
1
Astellas Pharma Inc., Tokyo, Japan. ichiro.nakamura@astellas.com.
2
Department of Medicine, Shiga University of Medical Science, Shiga, Japan.
3
First Department of Internal Medicine, University of Toyama, Toyama, Japan.
4
Astellas Pharma Inc., Tokyo, Japan.
PMID:
34279807
PMCID:
PMC8496576
DOI:
10.1007/s12325-021-01813-8
No abstract available
Publication types
Published Erratum